RFP Scorecard for Healthcare AI Automation Vendors

Healthcare AI automation has crossed a threshold: the market is now crowded enough that vendor claims blur together, and unstructured procurement has become the biggest risk a practice takes on. MobiHealthNews executive predictions name 2026 as the year AI vendors get held accountable for measurable outcomes rather than promising pilots, and that shift from pilot to proof means a procurement decision now carries real financial and operational weight that can affect a practice's finances and operations if the tool underperforms. A vendor's RFP pitch rarely accounts for the change management a deployment actually demands. A system built correctly can still generate new work elsewhere in a practice if the organization has not prepared for it. The failure mode is not the software but the gap between installation and readiness.

That gap is not theoretical. Imprivata's survey found that a large majority of U.S. healthcare organizations already have AI tools or agents running without formal IT approval. Procurement disorder is the present condition of the industry, and a practice evaluating vendors today is doing so inside an environment where shadow deployments have already outpaced governance. A structured scorecard exists precisely because the alternative, buying on the strength of a demo and a sales deck, has already produced the chaos Imprivata documented.

What the scorecard is actually evaluating, and what it is not

A scorecard built for this purchase measures one thing above all: whether a vendor's agents can take ownership of administrative workflows end to end, inside the actual software a practice's staff already uses, rather than performing well in a controlled demonstration. That distinction matters because the category of software under evaluation, the autonomous agent, is defined by a specific set of behaviors. Kore.ai's analysis describes it as software that interprets intent, pulls context from EHRs and payer systems, decides next steps against policy and real-time inputs, executes actions across systems, tracks the task to completion, and escalates to a human when judgment is required.

That definition excludes more than it includes, and the exclusions are what keep an RFP from drifting into scope creep. Earlier chatbots and virtual assistants answered FAQs or ran scripted flows, and they stopped cold the moment a request fell outside predefined logic. RPA bots mimic a single human action without reasoning behind it, and API-dependent platforms need a formal integration project before they can touch anything at all. None of these qualify for the category this scorecard is built around. A July 2026 survey in the Journal of Biomedical Informatics found that most current AI agent research still lives in benchmark and controlled evaluation settings. That is exactly why a vendor demo so often reflects benchmark performance rather than what happens in a live clinic, and the scorecard exists to close that gap.

Just as important is what the scorecard refuses to touch. It covers administrative and operational workflows only, scheduling, prior authorization, claims and denial management, referral intake, cancellation recovery, and it stays away from clinical decision support or diagnostic AI entirely, because those carry a different set of regulatory and liability obligations. That boundary is not a limitation of the scorecard so much as the reason these systems are deployable in the first place: the compliance exposure in the back office is low enough to move quickly, while clinical AI remains a separate procurement exercise with its own standards. A practice administrator who lets a vendor blur that line, folding clinical claims into an administrative pitch, has already lost control of the evaluation.

How a vendor's deployment approach predicts whether it will work in your environment

Deployment method is the first criterion worth scoring, because it predicts almost everything that follows. The model a vendor uses determines whether automation goes live in weeks or turns into a multi-year integration project, and that difference is visible in the RFP long before a contract gets signed.

Computer-use agents represent one answer to this problem. These are systems that perceive a graphical interface visually, the way a staff member reads a screen, and then click, type, and navigate accordingly. They bypass the integration requirement altogether and work with whatever software is already open. Vendors like Novoflow go live across EHRs, payer portals, and third-party software this way, with a single login as the only technical prerequisite, no API connection and no workflow overhaul required. The alternative, API-dependent or EHR-native automation, only functions inside systems that expose an API, and that excludes most payer portals along with a long tail of legacy practice management platforms still in daily use, which stretches the implementation timeline considerably.

Neither approach is universally correct, and a scorecard that treats this as a binary of good versus bad deployment misses the actual question, which is fit. A large health system with a mature IT department and existing API infrastructure may reasonably tolerate a longer integration timeline in exchange for deep customization. An independent practice or a multi-location group usually cannot absorb that cost, in time or in staff attention, and needs a model that works with the systems already in place rather than requiring them to change.

The RFP questions that surface this reality are concrete. Ask whether the vendor requires API access, and to which systems specifically. Ask what the actual go-live timeline looks like counting from contract signature rather than from a vaguely defined "kickoff" date. Ask what the practice itself needs to do before the agent can run its first task. And ask directly whether the vendor has deployed before in an environment running the same EHR and payer mix this practice uses, since a vendor's track record in a different software environment says little about how it will perform in this one.

Whether a vendor's workflow coverage matches the administrative work that actually costs your practice money

Deployment method decides whether a vendor can get in the door. Workflow coverage decides whether the result is worth the effort. A vendor that automates a single step while leaving every surrounding step to staff has not actually solved anything, because the value of this category of software compounds only when it owns a complete workflow rather than an isolated task.

Prior authorization is the clearest example. The traditional process required a staff member to recognize that authorization was needed, track down the correct payer form, assemble clinical documentation, fill the form out by hand, submit it, and wait, often for days. Automation that only handles one piece of that chain, say, form lookup, leaves the rest of the burden exactly where it was. Automation that collapses the full sequence is a different proposition, and documented case studies of RPA-assisted PA submission show dramatic speed gains when the whole chain is covered rather than one link in it. The regulatory backdrop raises the stakes further: the CMS Interoperability and Prior Authorization Final Rule, CMS-0057-F, now requires payers to respond to standard prior authorization requests within a matter of days and urgent requests within hours, with full API-based electronic prior authorization required by January 2027. A vendor whose coverage stops short of the full PA workflow is asking a practice to absorb manual work in exactly the window where federal rules are tightening the clock.

Claims and denial management follows the same logic. A large share of denied claims are never resubmitted at all, which is revenue that simply disappears rather than revenue that gets fought for. Kore.ai's analysis identifies this category, reading claims, matching codes, flagging denials, as one of the clearest proven wins for agents already running in production. Scheduling and referral intake carry a comparable argument: agents that can answer and place calls, route intelligently, navigate a payer's phone tree, and book directly into the EHR go well beyond what a rules engine can do, because natural language understanding lets them handle the variation real callers introduce. A practice still running manual scheduling is losing patients to competitors who can offer faster access.

The production evidence for end-to-end coverage is specific rather than aspirational. At Avi Medical, Beam agents automate 81% of patient inquiries, thousands of tickets every week, with measurable effects on response time, cost per inquiry, and patient satisfaction, and none of that required the agent to make a single clinical decision. A workflow handled start to finish is the shape of the return a practice should be scoring for.

The RFP questions that surface this are direct. Ask which specific workflows the vendor automates end to end, and where exactly human handoff occurs within each one. Ask for a demonstration, live or recorded, of a complete workflow in an environment that matches this practice's own systems. And ask what happens when the workflow hits an exception, a payer portal that changed overnight, a missing document, an authorization requirement that does not fit the standard template, because that answer reveals more about production readiness than any demo reel.

Evaluating whether a vendor can work across every system in the workflow, not just the EHR

Fragmented systems are why administrative work costs as much as it does, and a vendor whose automation breaks the moment it steps outside the EHR has not solved interoperability. It has only relocated it. Every practice administrator already knows this friction firsthand: a scheduling platform that does not talk to the EHR, a payer portal with its own login and its own quirks, a clearinghouse that requires yet another manual step. None of those systems were built to cooperate, and staff spend real hours each week bridging the gaps between them by hand.

Interoperability is shifting from a data-exchange problem into a data-usability problem, and installing a new system can force changes to data structure, clinical workflow, staffing, and financial operations long after the technology itself has gone live. That has a direct consequence for an RFP. A vendor who insists on formal API integration with every payer portal, every clearinghouse, and every third-party platform in the workflow will eventually run into the same fragmentation the practice is trying to escape, because most of those systems either do not expose an API or expose one inconsistently from payer to payer.

Screen-operating agents answer this differently. Because they perceive and operate a graphical interface the same way a staff member does, reading, clicking, typing, navigating, the agent's reach extends to anything a staff member can log into, with no integration project standing between the two. This is the shift that most directly predicts whether automation will actually function in a given environment: it treats interoperability as something achieved through how the agent operates, not through how many systems happen to expose APIs. Platforms like Novoflow, which work across EHRs, payer portals, and third-party systems without requiring integrations or workflow changes, illustrate why this architecture, rather than isolated task automation, deserves to be a primary criterion in the RFP itself. Novoflow's agents interact with these systems requiring only a login, not an integration project, which is a meaningfully different commitment than a platform asking a practice to wait on a development cycle before the first task can run.

The questions that surface genuine interoperability coverage are specific enough to resist a vague answer. List every system the workflow touches, EHR, payer portal, clearinghouse, scheduling platform, practice management software, and ask the vendor to confirm exactly how its agent interacts with each one. Ask whether the vendor requires an API connection, a custom integration, or an HL7/FHIR feed for any system in that list. Ask what happens when a payer portal changes its interface overnight, and who at the vendor is responsible for the agent adapting to it. And ask whether the vendor has actually operated in this specific EHR and payer combination before, since general claims about interoperability mean little without a track record in the practice's own environment.

What a vendor's compliance posture requires you to verify before signing

HIPAA certification and SOC 2 Type II belong on every vendor's baseline checklist, but neither one differentiates a serious vendor from a mediocre one. They are the price of entry. The compliance questions that actually separate vendors concern what the agent does with protected health information while it is running.

HIPAA's Privacy and Security Rules apply to any AI tool that touches PHI, and that includes model training processes, third-party MLOps tools, and every vendor integration in the chain. No AI-specific HIPAA rule exists, but the existing rules reach every touchpoint an agent creates. A signed data-protection agreement with every vendor is required across the board, not as an optional add-on.

A short set of questions should settle whether a vendor meets that bar. Will the vendor sign a BAA at all, and is it a zero-data-retention BAA specifically built for AI automation? Is patient information encrypted end to end and hosted in a private, single-tenant environment? Is the practice's PHI ever used to train a foundation model, whether the vendor's own or a third-party model elsewhere in the stack? What certifications does the vendor actually hold, and are they current: SOC 2 Type II and HIPAA compliance are the floor, and a serious evaluation asks for the audit date and its scope rather than taking the claim at face value. How does the vendor log every action an agent takes, and can the practice access those logs when an audit demands it? And what is the vendor's incident response protocol if PHI is exposed during agent operation?

Novoflow holds both SOC 2 Type II certification and HIPAA compliance, treating them as non-negotiable baseline requirements rather than marketing language, and its deployment model keeps PHI inside the practice's existing system boundaries instead of routing patient data through an external training pipeline. That architecture choice answers one of the harder questions on the list above before the vendor is ever asked it directly.

The regulatory environment is only going to tighten this requirement further. The CMS Interoperability and Prior Authorization Final Rule adds a federal timeline to a process that compliance teams used to be able to negotiate informally with each payer, and any vendor touching prior authorization now operates inside that deadline whether its contract says so explicitly or not. A practice that signs with a vendor unable to answer the questions above in specific, verifiable terms is inheriting a compliance liability it has not yet priced.